Diabetes Devices Market Size & Share, by Type (Blood Glucose Monitoring, Insulin Delivery Devices); Technology; End user; Application; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Diabetes Devices Market - Regional Analysis

North America Market Insights

The North America diabetes devices market is predicted to account for the largest revenue share of 35.7% during the forecast period. The leadership of the region is effectively attributable to established clinical guidelines and reimbursement mechanisms that support diabetes device adoption. The region’s market is also supported by the U.S. FDA approvals for over-the-counter wearable sensors.  As per the article published by ADA in June 2025, in a span of four years, Medicare fee‑for‑service beneficiaries with type 1 diabetes showed rising use of diabetes management devices. It states that among 321,000 patients, two‑thirds were aged above 65, and the prevalence of type 1 diabetes increased from 0.55% to 0.63%. Besides, the device usage grew from 43.3% to 59.9%, with yearly rise being 2.2% to 5.5%, which is largely driven by continuous glucose monitor adoption. About half of the devices were dependent on both CGMs and insulin pumps, reflecting Medicare’s expanded coverage and growing acceptance of advanced technologies.

The diabetes devices market in the U.S. is growing due to continued technological innovations and generous government funds. The market is currently making a shift from traditional monitoring toward integrated ecosystems that combine wearable sensors with automated insulin delivery systems. In February 2026, Congress passed bipartisan legislation extending the Special Diabetes Program (SDP) through December 2026, thereby increasing annual funding from USD 160 million to USD 200 million and boosting NIH diabetes research funding by a total of USD 10 million. The SDP, created by Congress and administered by the NIH, has contributed nearly USD 3.6 billion to type 1 diabetes (T1D) research, supporting breakthroughs and the first therapy shown to delay T1D onset. The article highlights that SDP has generated an amount of USD 50 billion in healthcare savings, underscoring its strong impact on patients, research, and taxpayers.

Expanding provincial and territorial coverage is the main factor which is responsible for the overall diabetes devices market growth in Canada. The market is evolving as government initiatives and private insurers are subsidizing wearable technologies to improve long-term health outcomes. In this context, in February 2024, the country’s government,  through Bill C-64, announced that it is moving toward universal pharmacare by providing single-payer coverage for essential diabetes medications in partnership with willing provinces and territories.  Along with this, a federal fund will support access to diabetes devices and supplies such as syringes, insulin pumps, glucometers, and continuous glucose monitors. This program standardizes coverage and affordability, and it aims to reduce the financial burden on patients and cost savings for the healthcare system.

APAC Market Insights

The Asia Pacific diabetes devices market is seeing rapid growth, propelled by rising health consciousness among the middle-class population. The region is characterized by the emergence of affordable domestic manufacturers along with localized production hubs, which are mainly aimed at addressing price-sensitive rural and semi-urban populations. Based on the government data from Japan, in January 2026, Light Touch Technology (LTT) Inc. developed a non-invasive blood glucose sensor using advanced mid-infrared laser technology. This particular device measures glucose levels through a fingertip in just five seconds by eliminating the need for painful blood draws and reducing infection risks.  Hence, such instances indicate that the Asia Pacific is becoming a hub for patient-friendly healthcare solutions, wherein the continued advancements by local startups are addressing both medical needs and affordability.

The government initiatives for better, more accessible healthcare are driving the diabetes devices market in China. The country’s market also benefits from insatiable demand for CGM systems, insulin pumps, and digital health tools, which are influenced by the rise of e-commerce platforms, and they have become key distribution channels along with traditional hospital sales. In July 2024, the Healthy China Action diabetes prevention and control implementation plan 2024 to 2030 highlighted that prevention is highly essential by integrating medical treatment with public health education, and strengthening healthcare. It outlines measures such as nationwide awareness campaigns, early screening, standardized diagnosis and treatment, and the use of both traditional domestic and Western medications. In addition, by 2030, the plan aims to improve diabetes management, reduce complications, and build a supportive environment that enhances public health literacy and lowers the disease burden.

The diabetes devices market in India is gaining increased exposure owing to the presence of a large patient base, high-tech adoption in urban centers, and basic monitoring in rural areas.  The rise in terms of telemedicine and mobile health apps is readily transforming the sector, as patients in the country look for digital ecosystems that provide remote doctor consultations along with glucose data tracking. As stated by Press Information Bureau (PIB) in January 2026, the Government of India, through the Technology Development Board (TDB) and Department of Science & Technology, entered into a partnership with Drstore Healthcare Service India Pvt. Ltd., and it is a collaborative R&D Programme to develop an advanced continuous glucose monitoring device incorporated with cardiovascular biomarkers. This innovation aims to enable monitoring of both diabetes and heart health, thereby supporting early detection and preventive care. Therefore, such projects strengthen India’s digital health ecosystem and promote affordable, scalable healthcare solutions.

Europe Market Insights

Europe diabetes devices market is forecasted to emerge as a powerful region in the global dynamics. The region’s growth is mainly attributable to universal healthcare systems and a strong emphasis on long-term cost-effectiveness. The government-led reimbursement programs drive the integration of automated insulin delivery systems and closed-loop technologies. As per the official data published in February 2026, the International Diabetes Federation (IDF) Europe is driving integrated, person-centred diabetes action across the continent, aligning with major regional and WHO initiatives. The focus is on breaking siloed care by linking diabetes with cardiovascular disease and other NCDs. Besides, IDF Europe is prioritizing innovation by advocating for simplified clinical trials. At the same time, it calls for robust oversight of medical devices and an Innovation Pathway to fast-track safe, effective breakthrough technologies for people with diabetes, hence making it suitable for standard diabetes devices market growth.

A highly structured statutory health insurance system that provides coverage for advanced technologies is rearranging the growth dynamics of the diabetes devices market in Germany. The national guidelines now prioritize continuous monitoring and pump therapy for a broad patient demographic. In the context, the country’s statutory health insurer, KKH, in April 2024  announced the expansion of coverage to include Abbott’s FreeStyle Libre 3 continuous glucose monitoring system for people with type 2 diabetes on basal insulin-supported oral therapy. This marks the first time CGM devices are reimbursed for such patients, thereby offering a painless alternative to routine blood tests, whereas the initiative aims to improve glucose control and prevent complications. From a strategic perspective, such instances in the country denote that policy-driven access to advanced diabetes technologies is a key factor that is responsible for reshaping diabetes devices market growth and adoption dynamics.

The UK diabetes devices market is strongly supported by a push for integrated care systems, where wearable sensors and insulin pumps are linked to digital platforms to streamline data sharing between patients and clinical teams. The country is considered to be a major hub for closed-loop technology trials, which is fostering a dynamic environment where manufacturers focus on cost-effectiveness in the long term. In January 2024, National Health Service England published a 5-year implementation strategy for hybrid closed-loop technologies by linking continuous glucose monitoring with insulin pumps, with the main goal to support people with type 1 diabetes.  The phased rollout is focused on equitable access, targeting patients most likely to benefit, children, pregnant women, and adults with high HbA1c or disabling hypoglycaemia. The strategy also concentrates on workforce training, patient education, and cost-effective procurement in line with NICE guidance, whereas specialist centres lead in terms of early adoption.